Malignant pleural effusion: from bench to bedside

被引:187
|
作者
Psallidas, Ioannis [1 ]
Kalomenidis, Ioannis [2 ]
Porcel, Jose M. [3 ]
Robinson, Bruce W. [4 ,5 ]
Stathopoulos, Georgios T. [6 ,7 ,8 ,9 ]
机构
[1] Oxford Univ Hosp Trust, Oxford Ctr Resp Med, Oxford Resp Trials Unit, Oxford, England
[2] Univ Athens, Sch Med, Evangelismos Hosp, Dept Crit Care & Pulm Med 1, Athens, Greece
[3] Arnau de Vilanova Univ Hosp, Biomed Res Inst Lleida, Dept Internal Med, Pleural Med Unit, Lleida, Spain
[4] Univ Western Australia, Sch Med & Pharmacol, Natl Ctr Asbestos Related Dis, Perth, WA, Australia
[5] Sir Charles Gairdner Hosp, Dept Resp Med, Nedlands, WA, Australia
[6] Univ Patras, Fac Med, Dept Physiol, Lab Mol Resp Carcinogenesis, Achaia, Greece
[7] Ludwig Maximilians Univ Munchen, Univ Hosp, Comprehens Pneumol Ctr CPC, Munich, Germany
[8] Helmholtz Zentrum Munchen, Munich, Germany
[9] German Ctr Lung Res DZL, Munich, Germany
基金
欧洲研究理事会;
关键词
MESOTHELIAL CELLS; T-CELLS; DIFFERENTIAL-DIAGNOSIS; LUNG ADENOCARCINOMA; CYTOTOXIC ACTIVITY; TALC PLEURODESIS; MOUSE MODEL; CHEST TUBE; EFFICACY; SURVIVAL;
D O I
10.1183/16000617.0019-2016
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Malignant pleural effusion (MPE) is a common but serious condition that is related with poor quality of life, morbidity and mortality. Its incidence and associated healthcare costs are rising and its management remains palliative, with median survival ranging from 3 to 12 months. During the last decade there has been significant progress in unravelling the pathophysiology of MPE, as well as its diagnostics, imaging, and management. Nowadays, formerly bed-ridden patients are genotyped, phenotyped, and treated on an ambulatory basis. This article attempts to provide a comprehensive overview of current advances in MPE from bench to bedside. In addition, it highlights unanswered questions in current clinical practice and suggests future directions for basic and clinical research in the field.
引用
收藏
页码:189 / 198
页数:10
相关论文
共 50 条
  • [21] Management of Malignant Pleural Effusion
    Kastelik, Jack A.
    LUNG, 2013, 191 (02) : 165 - 175
  • [22] Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion
    Verma, Akash
    Phua, Chee Kiang
    Sim, Wen Yuan
    Algoso, Reyes Elmer
    Tee, Kuan Sen
    Lew, Sennen J. W.
    Lim, Albert Y. H.
    Goh, Soon Keng
    Tai, Dessmon Y. H.
    Kor, Ai Ching
    Ho, Benjamin
    Abisheganaden, John
    MEDICINE, 2016, 95 (26)
  • [23] Quantitative proteomics revealed protein biomarkers to distinguish malignant pleural effusion from benign pleural effusion
    Dong, Tingyan
    Liang, Yueming
    Chen, Hui
    Li, Yanling
    Li, Zhiping
    Gao, Xinglin
    JOURNAL OF PROTEOMICS, 2024, 302
  • [24] Malignant Pleural Effusion: Diagnosis and Treatment-Up-to-Date Perspective
    Orlandi, Riccardo
    Cara, Andrea
    Cassina, Enrico Mario
    Degiovanni, Sara
    Libretti, Lidia
    Pirondini, Emanuele
    Raveglia, Federico
    Tuoro, Antonio
    Vaquer, Sara
    Rizzo, Stefania
    Petrella, Francesco
    CURRENT ONCOLOGY, 2024, 31 (11) : 6867 - 6878
  • [25] An improved method of delivering a sclerosing agent for the treatment of malignant pleural effusion
    Beck, Tim N.
    Deneka, Alexander Y.
    Chai, Louis
    Kanach, Colin
    Johal, Priya
    Alvarez, Nicolas J.
    Boumber, Yanis
    Golemis, Erica A.
    Laub, Glenn W.
    BMC CANCER, 2019, 19 (1)
  • [26] Contemporary approach to the patient with malignant pleural effusion complicating lung cancer
    Epelbaum, Oleg
    Rahman, Najib M.
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (15)
  • [27] Safety Profile of the Use of Iodopovidone for Pleurodesis in Patients with Malignant Pleural Effusion
    Andrade Neto, Jose Dias
    Terra, Ricardo Mingarini
    Teixeira, Rodrigo Maia
    Pereira, Sylvana Vianna
    Pego-Fernandes, Paulo Manuel
    RESPIRATION, 2015, 90 (05) : 369 - 375
  • [28] Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion
    Tsuji, S.
    Tsuura, Y.
    Morohoshi, T.
    Shinohara, T.
    Oshita, F.
    Yamada, K.
    Kameda, Y.
    Ohtsu, T.
    Nakamura, Y.
    Miyagi, Y.
    BRITISH JOURNAL OF CANCER, 2010, 103 (04) : 517 - 523
  • [29] Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion
    S Tsuji
    Y Tsuura
    T Morohoshi
    T Shinohara
    F Oshita
    K Yamada
    Y Kameda
    T Ohtsu
    Y Nakamura
    Y Miyagi
    British Journal of Cancer, 2010, 103 : 517 - 523
  • [30] Malignant pleural effusion: current understanding and therapeutic approach
    Gonnelli, Francesca
    Hassan, Wafa
    Bonifazi, Martina
    Pinelli, Valentina
    Bedawi, Eihab O.
    Porcel, Jose M.
    Rahman, Najib M.
    Mei, Federico
    RESPIRATORY RESEARCH, 2024, 25 (01)